Valentina Ruggeri, a two-year-old girl from Australia, is living with an extremely rare genetic disorder called hyaline fibromatosis syndrome (HFS), which has made her medical journey uniquely challenging. HFS is caused by mutations in the ANTXR2 gene, leading to abnormal deposits of hyaline protein beneath the skin and in joints, bones, and internal organs. This condition, which can be fatal in children, has been diagnosed in only a few hundred people worldwide, with Valentina believed to be the sole case confirmed in Australia.

Valentina’s parents, Domenico and Sara Ruggeri, first noticed issues during pregnancy when a shortened femur was detected via ultrasound. At birth, while Valentina initially appeared healthy, her loud crying during delivery prompted concern from medical staff; it was later understood that certain movements caused her pain. By four months of age, she displayed symptoms including difficulty gaining weight, a rash-like appearance on her face, and persistent distress, although initial tests ruled out common neurological or metabolic conditions such as cerebral palsy and cystic fibrosis.

Her case was referred to neurogenetic researchers led by Gina Ravenscroft at a team based in Perth. Genetic analysis revealed that Valentina carried two variants within her ANTXR2 gene. These mutations had not been previously reported in any other individuals, making their clinical significance initially unclear. The discovery highlighted the rarity of her condition and underscored the challenges facing clinicians in diagnosing and managing such unusual genetic disorders.

Despite the severity of her diagnosis, Valentina’s parents describe her as lively and spirited. She demonstrates early language abilities, including counting to ten in three different languages, and enjoys activities like singing and picking flowers for her mother. While the long-term prognosis for children with HFS can be serious, her family is committed to providing her with care and support that enable her to live as fully as possible.

The scarcity of cases worldwide poses difficulties in establishing standardized treatments or interventions for HFS. Medical teams continue to document Valentina’s condition closely, contributing valuable information to the limited global understanding of this rare disease. As research progresses, families like the Ruggeris hope that advances in genetic medicine will offer improved options and outcomes for affected children.